| Mrs Christa Christensen, NP | |
|
2400 32nd Ave S, Fargo, ND 58103-5800 | |
| (701) 234-8830 | |
| Not Available |
| Full Name | Mrs Christa Christensen |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 9 Years |
| Location | 2400 32nd Ave S, Fargo, North Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275908196 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | R37106 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Medical Center Fargo | Fargo, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Medical Center Fargo | 8426967803 | 1094 |
News Archive
LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services including purpose-built LIMS that allow labs to go live faster and at a lower total cost, today announced the availability of its new purpose-built COVID-19 LIMS solution.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
Scientists from the University of Delaware have made a significant advance in the study of small ribonucleic acids (RNAs), discovering 10 times more small RNAs in the plant Arabidopsis than previously had been identified. The advance is reported in the Sept. 2 issue of Science magazine.
"The health-care overhaul gained popularity from May to June, according to a new tracking poll." The poll, conducted by the Kaiser Family Foundation "found that 48 percent of the public had a favorable view of the law in June while 41 percent had an unfavorable opinion." (Kaiser Health News is a program of the foundation.) In May, the tracking poll had found "41 percent favorable to 44 percent unfavorable."
Patients, families and caregivers are invited to attend an educational conference covering many aspects of brain tumors May 14 at Cedars-Sinai Medical Center.
› Verified 7 days ago
| Entity Name | Sanford Clinic North |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942241351 PECOS PAC ID: 4284546151 Enrollment ID: O20031112000221 |
News Archive
LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services including purpose-built LIMS that allow labs to go live faster and at a lower total cost, today announced the availability of its new purpose-built COVID-19 LIMS solution.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
Scientists from the University of Delaware have made a significant advance in the study of small ribonucleic acids (RNAs), discovering 10 times more small RNAs in the plant Arabidopsis than previously had been identified. The advance is reported in the Sept. 2 issue of Science magazine.
"The health-care overhaul gained popularity from May to June, according to a new tracking poll." The poll, conducted by the Kaiser Family Foundation "found that 48 percent of the public had a favorable view of the law in June while 41 percent had an unfavorable opinion." (Kaiser Health News is a program of the foundation.) In May, the tracking poll had found "41 percent favorable to 44 percent unfavorable."
Patients, families and caregivers are invited to attend an educational conference covering many aspects of brain tumors May 14 at Cedars-Sinai Medical Center.
› Verified 7 days ago
| Entity Name | Sanford Medical Center Fargo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184917924 PECOS PAC ID: 8426967803 Enrollment ID: O20110331000495 |
News Archive
LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services including purpose-built LIMS that allow labs to go live faster and at a lower total cost, today announced the availability of its new purpose-built COVID-19 LIMS solution.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
Scientists from the University of Delaware have made a significant advance in the study of small ribonucleic acids (RNAs), discovering 10 times more small RNAs in the plant Arabidopsis than previously had been identified. The advance is reported in the Sept. 2 issue of Science magazine.
"The health-care overhaul gained popularity from May to June, according to a new tracking poll." The poll, conducted by the Kaiser Family Foundation "found that 48 percent of the public had a favorable view of the law in June while 41 percent had an unfavorable opinion." (Kaiser Health News is a program of the foundation.) In May, the tracking poll had found "41 percent favorable to 44 percent unfavorable."
Patients, families and caregivers are invited to attend an educational conference covering many aspects of brain tumors May 14 at Cedars-Sinai Medical Center.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Christa Christensen, NP Po Box 2010, Fargo, ND 58122-2484 Ph: (701) 234-8830 | Mrs Christa Christensen, NP 2400 32nd Ave S, Fargo, ND 58103-5800 Ph: (701) 234-8830 |
News Archive
LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services including purpose-built LIMS that allow labs to go live faster and at a lower total cost, today announced the availability of its new purpose-built COVID-19 LIMS solution.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
Scientists from the University of Delaware have made a significant advance in the study of small ribonucleic acids (RNAs), discovering 10 times more small RNAs in the plant Arabidopsis than previously had been identified. The advance is reported in the Sept. 2 issue of Science magazine.
"The health-care overhaul gained popularity from May to June, according to a new tracking poll." The poll, conducted by the Kaiser Family Foundation "found that 48 percent of the public had a favorable view of the law in June while 41 percent had an unfavorable opinion." (Kaiser Health News is a program of the foundation.) In May, the tracking poll had found "41 percent favorable to 44 percent unfavorable."
Patients, families and caregivers are invited to attend an educational conference covering many aspects of brain tumors May 14 at Cedars-Sinai Medical Center.
› Verified 7 days ago
Wendy M Moore, NURSE PRACTITIONER Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 901 28th St S, Fargo, ND 58103 Phone: 701-404-1100 Fax: 701-540-6498 | |
Mrs. Kayla L. Nelson, DNP, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 301 Np Ave N, Fargo, ND 58102 Phone: 701-271-3344 | |
Kyrie Marie Severson, APRN, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4622 40th Ave S, Suite A, Fargo, ND 58104 Phone: 701-364-2909 Fax: 701-364-9822 | |
Sadie Marie Nelson, APRN, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: Sanford Broadway Clinic, 801 North Broadway, Fargo, ND 58102 Phone: 701-234-2000 | |
Jessica Smolen, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 321 8th Ave N, Fargo, ND 58102 Phone: 701-234-2525 | |
Mr. Nicholas Henry Frederiksen, APRN,CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3000 32nd Ave S, Fargo, ND 58103 Phone: 701-364-8000 Fax: 701-364-8078 | |
Erin Marie Wilmes Reiniger, APRN, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4671 38th St S, Fargo, ND 58104 Phone: 701-404-5100 Fax: 701-499-1166 |